NYSE: PFE
Pfizer Inc Stock

PFE Price
$37.08
Fair Value Price
N/A
Market Cap
$205.97B
52 Week Low
$28.49
52 Week High
$40.71
P/E
14.54x
P/B
3.20x
P/S
3.62x
PEG
2.57x
Dividend Yield
3.99%
Revenue
$49.20B
Earnings
$14.17B
Gross Profit Margin
79.90%
Operating Margin
34.62%
Net Profit Margin
28.80%
Debt to Equity
1.76
Operating Cash Flow
$15B
Beta
0.71
Next Earnings
Oct 27, 2020
Ex-Dividend
Nov 5, 2020
Next Dividend
Dec 1, 2020

Zen Score

High
Medium
Low
54
Industry average

Reasons for this score

PFE ($37.08) is trading below its intrinsic value of $95.96, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
PFE is good value based on its earnings relative to its share price (14.54x), compared to the US market average 38.92x)
Valuation
PFE is good value based on its earnings relative to its share price (14.54x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

1 of 13

PFE News

Valuation

PFE price to earnings (PE)

For valuing profitable companies with steady earnings
Company
14.54x
Industry
-11.07x
Market
38.92x
PFE is good value based on its earnings relative to its share price (14.54x), compared to the US market average 38.92x)
Valuation
PFE is good value based on its earnings relative to its share price (14.54x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

PFE price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.20x
Industry
7.85x
Market
65.04x
PFE is good value based on its book value relative to its share price (3.20x), compared to the US market average (65.04x)
Valuation
PFE is good value based on its book value relative to its share price (3.20x), compared to the US Drug Manufacturers - General industry average (7.85x)
Valuation

PFE price to earnings growth (PEG)

For valuing profitable companies with growth potential
PFE is poor value relative to its rate of earnings growth, measured by PEG ratio (2.57x)
Valuation

PFE's financial health

Profit margin

Revenue
$12.0B
Net Income
$3.4B
Profit Margin
28.30%
PFE's Earnings (EBIT) of $17.03B can safely cover interest payments on company debt ($63.61B)
Financials
PFE's profit margin has increased (+5.20%) in the last year from (23.60%) to (28.80%)
Financials

Assets to liabilities

Assets
$166.3B
Liabilities
$101.0B
Debt to equity
0.80
PFE's short-term assets ($46.42B) exceed its short-term liabilities ($32.72B)
Financials
PFE's long-term liabilities ($80.65B) exceed its short-term assets ($46.42B)
Financials
PFE's debt has increased relative to shareholder equity (1.76), over the past 5 years ago (1.40)
Financials
PFE's debt to equity ratio (1.76) is considered high
Financials

Cash flow

Operating
$3.1B
Investing
-$71.0M
Financing
-$2.2B
PFE's operating cash flow ($14.97B) is sufficient to service the company's debt ($63.61B)
Financials

Pfizer Stock FAQ

(NYSE: PFE) Pfizer trades on the NYSE under the ticker symbol PFE. Pfizer stock quotes can also be displayed as NYSE: PFE.
(NYSE: PFE) Pfizer stock price per share is $37.08 today (as of Oct 21, 2020).
(NYSE: PFE) Pfizer's 52-week high was $40.71, and its 52-week low was $28.49. It is currently -8.92% from its 52-week high and 30.15% from its 52-week low.
(NYSE: PFE) Pfizer's market cap is $205.97B, as of Oct 22, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Pfizer's market cap is calculated by multiplying PFE's current stock price of $37.08 by PFE's total outstanding shares of 5,554,833,754.
(NYSE: PFE) Pfizer currently has 5,554,833,754 outstanding shares. With Pfizer stock trading at $37.08 per share, the total value of Pfizer stock (market capitalization) is $205.97B.

Pfizer stock was originally listed at a price of $24.85 in Dec 31, 1997. If you had invested in Pfizer stock at $24.85, your return over the last 22 years would have been 49.20%, for an annualized return of 1.84%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics